Analysts at StockNews.com started coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Nymox Pharmaceutical Stock Performance
Shares of Nymox Pharmaceutical stock opened at $0.34 on Thursday. The firm has a market capitalization of $30.60 million, a price-to-earnings ratio of -3.38 and a beta of 0.81. Nymox Pharmaceutical has a fifty-two week low of $0.19 and a fifty-two week high of $1.49. The stock has a 50 day moving average of $0.39 and a 200 day moving average of $0.38.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Nymox Pharmaceutical stock. Citigroup Inc. acquired a new position in Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 109,079 shares of the biopharmaceutical company’s stock, valued at approximately $137,000. Citigroup Inc. owned 0.12% of Nymox Pharmaceutical as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.78% of the company’s stock.
About Nymox Pharmaceutical
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Penny Stock Wag! Group Co. Has Solid Sell-Side Support
- Staples Stocks Get Lift From Conagra Results, New Highs In Sight
- SGH Bottomed, But Can It Reverse And Move Higher?
- Is Pinterest Showing Signs of an Improving Ad Market?
- At 3x Earnings, Avis Budget Is Worth Taking for a Spin
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
